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ACTH = adrenocorticotrophic hormone; ALI = acute lung injury; AMI = acute myocardial infarction; APACHE = Acute Physiology and Chronic
Health Evaluation; ARDS = acute respiratory distress syndrome; CVP = central venous pressure; EGDT = early goal-directed therapy; FiO2 =
fraction of inspired oxygen; ICU = intensive care unit; IFN = interferon; IL = interleukin; MAP = mean arterial pressure; PEEP = positive end-
expiratory pressure; PROWESS = Protein C Worldwide Evaluation in Severe Sepsis; ScvO2 = central venous oxygen saturation; TNF = tumor
necrosis factor.
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Introduction
Sepsis is the tenth most common cause of death in the US
[1]. A recent US study reported that severe sepsis accounts
for in excess of 215,000 deaths annually from a total popula-
tion of approximately 750,000 patients—a mortality rate of
approximately 29% (with published studies quoting a range
of 28–50%) [2].
This persistent, high mortality rate is clearly unacceptable,
given that it ranks sepsis above some of the higher profile
causes of in-hospital death, including stroke (12–19% risk of
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Abstract
Considerable progress has been made in the past few years in the development of therapeutic
interventions that can reduce mortality in sepsis. However, encouraging physicians to put the results of
new studies into practice is not always simple. A roundtable was thus convened to provide guidance
for clinicians on the integration and implementation of new interventions into the intensive care unit
(ICU). Five topics were selected that have been shown in randomized, controlled trials to reduce
mortality: limiting the tidal volume in acute lung injury or acute respiratory distress syndrome, early goal-
directed therapy, use of drotrecogin alfa (activated), use of moderate doses of steroids, and tight
control of blood sugar. One of the principal investigators for each study was invited to participate in the
roundtable. The discussions and questions that followed the presentation of data by each panel
member enabled a consensus recommendation to be derived regarding when each intervention should
be used. Each new intervention has a place in the management of patients with sepsis. Furthermore,
and importantly, the therapies are not mutually exclusive; many patients will need a combination of
several approaches—an ‘ICU package’. The present article provides guidelines from experts in the field
on optimal patient selection and timing for each intervention, and provides advice on how to integrate
new therapies into ICU practice, including protocol development, so that mortality rates from this
disease process can be reduced.
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death in the first 30 days) and acute myocardial infarction
(AMI) (8% risk of death in the first 30 days) [3]. Moreover, the
actual number of deaths associated with the condition may
be even higher than current estimates suggest. Many sepsis
patients have at least one comorbidity and deaths are often
attributed to these conditions rather than to sepsis [4–6].
Unfamiliarity with the signs and symptoms of sepsis may
further hinder accurate diagnosis.
There are many possible reasons for this high mortality. Sepsis
is certainly a complex disease state; the pathophysiology is
only now beginning to be unraveled, and it is complicated by
heterogeneous presentation (possible signs of sepsis are pre-
sented in Table 1). While none of these signs alone is specific
for sepsis, the otherwise unexplained presence of these signs
should signal the possibility of a septic response.
Many cases of sepsis are recognized late, and patients are
often inappropriately treated before entering the intensive
care unit (ICU) by physicians unfamiliar with the signs and
symptoms of the condition. Furthermore, treatment may be
initiated by any of a number of physicians (anesthetists,
hematologists, intensivists, infectious disease specialists,
pulmonologists, and emergency physicians). There are
presently various defined supportive strategies for treating
patients with sepsis, but improvements are needed to reduce
the unacceptably high mortality rate.
Moreover, as with other areas of medicine, the application
and integration of new but proven strategies for reducing
morbidity and mortality into clinical practice has been slow.
Encouraging new data have recently been presented on new
approaches to the management of patients with sepsis. Many
of these approaches attempt to modulate or interrupt the
sepsis cascade and to address the cause of multiorgan dys-
function. Although many of these approaches are in early
phases of development (e.g. antibodies to tumor necrosis
factor [TNF] alpha, bactericidal permeability increasing
protein, high-flow hemofiltration to remove circulating inflam-
matory mediators, platelet-activating factor acetyl hydrolase,
and antielastases), other approaches are more advanced and
are already beginning to impact on outcomes in the ICU.
At a roundtable discussion in London in June 2002, Professor
Jean-Louis Vincent brought together five experts to discuss
more effective implementation of five exciting new inter-
ventions in the ICU setting to decrease the unacceptable
burden of mortality in patients with severe sepsis.
Each of the roundtable panelists is a highly respected physi-
cian in the world of sepsis and critical care medicine. The inter-
ventions discussed encompassed low tidal volume in patients
with acute lung injury (ALI)/acute respiratory distress syndrome
(ARDS) (Edward Abraham), early goal-directed therapy
(EGDT) (Emanuel Rivers), drotrecogin alfa (activated) (Gordon
Bernard), moderate-dose corticosteroids (Djillali Annane), and
tight control of blood sugar (Greet Van den Berghe).
Objectives
The purpose of the roundtable discussion was to provide
guidance for clinicians on the integration of new interventions
into the ICU to reduce the mortality in sepsis, on appropriate
patient selection for these interventions, and on appropriate
timing of these interventions.
The present review reports the discussions and recommen-
dations of the panel.
Unacceptable mortality
The overall 30-day mortality in the ICU is typically ~20% [8].
The 30-day mortality in the population with severe sepsis,
defined as sepsis with organ dysfunction, is 30–50%. It is
clear from this figure that severe sepsis contributes dispro-
portionately to the overall 30-day mortality in the ICU and
compares unfavorably with some of the higher profile acute
killers in hospital (e.g. stroke and AMI) [3].  Despite the
general improvements in medicine overall, this mortality rate
has remained essentially unchanged for the past 25 years.
This has contributed to a feeling of pessimism among
Table 1
Possible signs of sepsis (adapted from [7])
Parameters Signs
General Fever, chills
Inflammatory Altered white blood cell count, increased serum concentrations of C-reactive protein or procalcitonin
Coagulopathy Increased D-dimers, low protein C, increased prothrombin time/activated partial thromboplastin time
Hemodynamic Tachycardia, increased cardiac output, low systemic vascular resistance, low oxygen extraction ratio
Metabolic Increased insulin requirements
Tissue perfusion Altered skin perfusion, reduced urine output
Organ dysfunction Increased urea and creatinine, low platelet count or other coagulation abnormalities, hyperbilirubinemiaS3
intensivists and other medical professionals regarding treat-
ment prospects for severe sepsis, and a reluctance to rapidly
incorporate new interventions into clinical practice [9].
Mortality reductions: slow and steady wins the race
Although the sepsis mortality rates are unacceptable, they
camouflage some significant developments that are and have
been occurring for hospital patients, for the general ICU popu-
lation and, particularly, for those with severe sepsis. Direct
comparison of mortality rates among patients with identical
Acute Pysiology and Chronic Health Evaluation (APACHE)
scores in the placebo arm of anti-TNF or anti-endotoxin
studies published 10–15 years ago [10–12] with more recent
studies [13,14], demonstrates that the mortality rate is much
lower in more recent studies. Interestingly, this decrease was
apparent even before the five interventions discussed in the
present article were published, reflecting improvements in the
general supportive care of sepsis patients.
Indeed, the panel contends that mortality from septic shock
has already been reduced. Some patients who in the recent
past would have died from severe sepsis or septic shock do
not reach the ICU now because they are well managed on
the wards, in the emergency department, and even during
preoperative and postoperative care. For example, those
sepsis patients that receive prompt antibiotic therapy have a
10–15% lower mortality rate than those who receive anti-
biotic therapy later in their care [15].
Progress is also being made in diagnosing sepsis: more
patients are being tested to identify the source of infection and
the pathogens involved, supportive care measures have been
improved (e.g. hemodynamic support), and other measures
have been put in place to reduce the incidence of nosocomial
infections (e.g. reducing the need for pulmonary artery
catheters by using echo techniques to assess cardiac func-
tion). There has also been a realization of the importance of
specially trained intensive care physicians in the ICU. It has
been internationally recognized that changing the ICU from an
‘open format’, whereby patients are cared for by their admitting
physician, to a ‘closed format’, whereby patients are managed
by appointed intensivists, reduces mortality rates [16].
Although the mortality rate is beginning to decline, it still
remains unacceptably high. Furthermore, the number of
patients with severe sepsis and septic shock is increasing;
people are living longer, and there has been a rise in the
number of immunocompromised patients due to aggressive
cancer therapy and the increased prevalence of HIV.
Learning from other specialties
In-hospital AMI-associated mortality rates averaged approxi-
mately 25–30% in the 1960s [3]. This clearly unacceptable
mortality rate was addressed by the development of a number
of new pharmacological and mechanical interventions
together with improvements in supportive care.
In the landmark Second International Study of Infarct Survival
trial, published in 1988, 17,187 suspected AMI patients were
treated with either streptokinase or aspirin, with both drugs,
or with neither. The mortality rate in the combination group of
this trial was 8%, compared with 13.2% in those patients
given neither streptokinase nor aspirin [17].
Cardiologists have effectively implemented multiple pharma-
cologic and supportive care interventions to reduce mortality
in AMI from 25–30% to 8% and lower. Not satisfied with this
already remarkable figure, they are trying to reduce it further.
Physicians treating patients with sepsis are clearly faced with
a very different situation to those treating patients with AMI,
and so direct comparisons are not possible. However, several
factors have contributed to the success of AMI therapy and
possibly to the lack of such success in sepsis (Table 2).
New interventions
Sepsis is undoubtedly complicated. However, many of the
lessons that have been learned through effective application
of therapies in other disease states can be applied to severe
sepsis. Furthermore, the encouraging data that are beginning
to appear in the literature indicate that sepsis may not be as
intractable to treat as once thought.
The following sections provide salient information on five
interventions that have shown a significant positive impact on
mortality rates in sepsis, severe sepsis, septic shock, or
sepsis-related diseases in recent clinical trials. The interven-
tions were presented at the roundtable by one of the principal
investigators of the key trial of the intervention. Each section
concludes with recommendations for the integration of the
particular intervention into clinical practice.
Low tidal volume in ALI/ARDS
Background
The traditional approach in patients with ALI/ARDS is to ven-
tilate using tidal volumes between 10 and 15 ml/kg body
weight, almost twice the average tidal volume at rest
(7–8 ml/kg body weight), and to maintain a low positive end-
expiratory pressure (PEEP). The purpose of this approach is
to achieve normal values for the pH and partial pressure of
arterial carbon dioxide. However, this method leads to high
inspiratory airway pressures and to excessive stretch of the
aerated lung.
In 1997, Tremblay et al. examined the effect of ventilation
strategy on lung inflammatory mediators in the presence and
absence of a pre-existing inflammatory stimulus in
Sprague–Dawley rats [18]. In both stimulated and non-
stimulated groups, the presence of inflammatory mediators
(TNF-α, IL-1β, IL-6, IL-10, macrophage inflammatory protein 2,
and IFN-γ) was highest in those rats ventilated with a large
tidal volume and zero PEEP. Furthermore, in a study by
Ranieri et al. in 1999 [19], the concentration of inflammatory
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mediators 36 hours after randomization of the groups was
significantly lower in the lung-protective strategy group (tidal
volume, 7.6 ± 1.1 ml/kg) than in the control group (tidal
volume, 11.1 ± 1.3 ml/kg) (P < 0.05).
Following on from the positive results in the Tremblay et al. trial
[18], a small study (53 patients) was carried out by Amato et al.
in Brazil [20]. The mortality rate was 38% in patients given ‘pro-
tective’ ventilation (PEEP above the lower inflection point on
the static pressure–volume curve, tidal volume <6 ml/kg ideal
body weight, driving pressures <20 cmH2O above the PEEP
value, permissive hypercapnia, and preferential use of pressure-
limited ventilatory modes) compared with 71% in patients on
conventional ventilation (P < 0.001). This impressive reduction
in mortality was tempered by the higher than normal mortality
level in the control group, prompting the National Institutes of
Health-funded Acute Respiratory Distress Syndrome Network
to set up a similar, larger (861 patients), prospective, multicen-
ter, randomized trial in the US [21].
Protocol
For a summary of the protocol used in this study, see
Appendix 1.
Key data
The trial was stopped after the fourth interim analysis
because the use of lower tidal volumes was found to be asso-
ciated with a significantly reduced mortality (P = 0.005 for the
difference in mortality between groups).
The primary endpoints were mortality prior to hospital dis-
charge with unassisted breathing and ventilator-free days
(days alive, off mechanical ventilation, between enrollment and
day 28). Both of these endpoints were achieved (Figs 1–3).
In addition, patients receiving a tidal volume of 6 ml/kg ideal
body weight had increased organ failure free days and lower
IL-6 levels.
Implications
ALI is seen in 25–42% of patients with sepsis [22]. Although
the approach has only been tested in patients with ALI/ARDS,
a tidal volume of 6 ml/kg ideal body weight is at the lower end
of the range of physiologic ventilation. Hence, this approach
should be suitable for most patients in the ICU setting.
Furthermore, as many patients with severe sepsis or septic
shock progress to frank ALI/ARDS, the panel believes that
low tidal volume therapy is a valid option in these patients,
and an option that may indeed prevent the development of
ALI/ARDS.
Although patient selection in the clinical trial specified both
blood gas and lung infiltrate criteria, at least 90% of patients
in the general ICU setting meet the criteria for blood gas but
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Table 2
A comparison of acute myocardial infarction (AMI) and sepsis
AMI Sepsis
Market issues Significant publicity surrounding and general awareness  Lack of understanding among physicians and the 
of the condition; large trials general public
Diagnosis A relatively straightforward and relatively common  Complicated by a long list of signs and symptoms 
diagnosis (electrocardiogram, enzymes, troponin), and  and few objective tools for validation
one that can be made by generalists, not just 
cardiology specialists
Comorbidities Generally single organ disease (notable exception when  Often chronic or acute comorbidities
complicated by cardiogenic shock)
Physician education Generalists have been taught to recognize the signs  Sepsis patients often come ‘second hand’ from a 
and symptoms of AMI; initial treatment is usually  specialist who may not be appropriately trained to 
provided by emergency physicians, who are trained  diagnose, manage, and refer patients with sepsis
to treat these patients
Figure 1
Mortality prior to hospital discharge in patients receiving a tidal volume
of 6 and 12 ml/kg ideal body weight.
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not those for infiltrates. At the Vanderbilt University School of
Medicine, patients receive low tidal volumes regardless of
whether they have bilateral infiltrates.
Further questions
Does low tidal volume ventilation increase the occurrence of
acidosis?
Acidosis is more likely to develop in patients with severe lung
problems rather than in those exhibiting milder disease when
tidal volumes are kept low. However, acidosis is seldom a
clinical problem and rarely requires administration of bi-
carbonates.
Is low tidal volume therapy distressing for the patient?
One of the issues with low tidal volume therapy is that the
patients are often more uncomfortable, at least initially, when
they are being ventilated with a tidal volume of 6 ml/kg ideal
body weight. The patients tend to exhibit tachypnea and may
become more agitated. Sedation is generally required, but
the ventilator setting can be maintained. Of more concern is
that ICU staff may consider a respiration rate of 40/min to be
a sign of something more serious and may attempt to termi-
nate the intervention. Education of staff is clearly essential.
Would provision of extrinsic PEEP cause hemodynamic
problems?
The strategy assessed in this trial not only includes ventilation
with a low tidal volume, but also the provision of extrinsic
PEEP. There may be some concern that an increased respira-
tory rate may result in intrinsic PEEP and hemodynamic prob-
lems (e.g. decreased cardiac filling, decreased cardiac
output, and diminished blood pressure). The panel believes
that auto PEEP was not an issue in the Acute Respiratory
Distress Syndrome Network study. In addition, in the groups
with low tidal volume, at least 10% more oxygen was required
to maintain the fraction of inspired oxygen (FiO2), suggesting
that there was very little auto PEEP occurring.
Recommendations of the panel
When mechanical ventilation is indicated for treatment of
patients with ALI/ARDS, the tidal volume should be limited to
~6 ml/kg ideal body weight.
Early goal-directed therapy (EGDT)
Background
Goal-directed therapy represents an attempt to adjust the
cardiac preload, afterload, and contractility to balance sys-
temic oxygen delivery with oxygen demand. In patients with
severe sepsis and septic shock, such an approach would
seem eminently reasonable as part of general supportive
measures to restore and maintain adequate cellular perfusion
and to prevent organ dysfunction. In the setting of the ICU,
however, supranormal and normal approaches have met with
little or no success [23,24]. It is possible that, by the time
these therapies are applied in the ICU, any such intervention
may have been too late. Hence, the focus has shifted towards
hemodynamic optimization in the early presentation of
disease, such as in the emergency department.
A prospective, randomized, predominantly blinded study was
initiated by the Early Goal-Directed Therapy Collaborative
Group to examine the results of hemodynamic interventions in
the emergency department [25]. In this study, patients were
randomly assigned to either 6 hours of EGDT or to standard
therapy prior to admission to the ICU.
Protocol
Baseline characteristics (including the adequacy and duration
of antibiotic therapy) in the EGDT and standard therapy
groups were not significantly different. The vital signs, resus-
citation endpoints, organ dysfunction scores, and coagula-
tion-related variables were similar in these groups at baseline
[25]. However, there were some important differences
between the treatment groups (see Table 3).
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Figure 2
Proportion of patients alive and off the ventilator having been ventilated
with a tidal volume of 6 and 12 ml/kg ideal body weight.
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Figure 3
Median number of ventilator-free days in patients receiving a tidal
volume of 6 and 12 ml/kg ideal body weight.
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Patients who were randomized to standard therapy received
a central venous pressure (CVP) arterial line as well as Foley
catheterization. The endpoints were adjusted for a CVP of
8–12 mmHg, a mean arterial pressure (MAP) >65 mmHg,
and a urine output of at least 0.5 ml/kg/hour.
Patients randomized to EGDT received the same therapy but,
in addition, were monitored for the endpoint of central venous
oxygen saturation (ScvO2) >70%. EGDT patients were given
more intravenous fluids (including blood transfusions) and
more inotropic support (mostly dobutamine).
For more information on the protocol used in this study, see
Appendix 2.
Key data
Key data are presented in Table 4. The in-hospital mortality
was 30.5% in the group assigned to EGDT and was 46.5%
in the group assigned to standard therapy (P = 0.009), indi-
cating that EGDT provides significant benefits in improving
outcomes in patients with severe sepsis and septic shock.
During the interval from 7 to 72 hours, patients assigned to
EGDT exhibited a more significant improvement in mean
ScvO2 (70.4 ± 10.7% versus 65.3 ± 11.4%), in lactate con-
centration (3.0 ± 4.4 mmol/l versus 3.9 ± 4.4 mmol/), in base
deficit (2.0 ± 6.6 mmol/l versus 5.1 ± 6.7 mmol/l), and in pH
(7.40 ± 0.12 versus 7.36 ± 0.12) than patients assigned to
standard therapy (P ≤ 0.02 for all comparisons). During the
same period, the mean APACHE II scores were significantly
lower, indicating less severe organ dysfunction, in the
patients assigned to EGDT than in those patients assigned to
standard therapy (13.0 ± 6.3 versus 15.9 ± 6.4, P < 0.001).
Implications
The protocol was based predominantly on guidelines pub-
lished in 1999 by the Society of Critical Care Medicine [26].
However, these guidelines have not been universally followed
in clinical practice since their publication. An increasing
number of critically ill patients are presenting to, and being
treated in, emergency departments [27,28]. This is present-
ing significant resource challenges in the emergency depart-
ment environment. The inability to institute EGDT may thus
not be a conscious decision by the clinician not to follow the
Society of Critical Care Medicine guidelines. Emergency
medicine in general may have to develop and formulate the
cost–benefit analysis to support or implement such care in
this environment in order to improve outcomes.
There are sufficient evidence-based data to recommend that
all patients with severe sepsis or septic shock should receive
early and aggressive resuscitation based on this EGDT proto-
col (see Appendix 2). It is important that the interventions are
individualized to each patient.
Further questions
Why was there no difference in mechanical ventilation or
vasopressor use between the standard treatment and EGDT
groups during the first 6 hours, but a large difference in fluid
transfusions and, especially, in dobutamine administration?
With a goal-oriented protocol, patients are stratified based on
hemodynamic derangements. Using measurements of ScvO2,
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Table 3
Therapeutic interventions: standard therapy versus EGDT
Intervention 0–6 hours 7–72 hours 0–72 hours
Fluid therapy (l) –2.49a +1.98b +0.085
Receiving vasopressors (%) +2.9 +13.8d +14.5c
Receiving inotropes (%) –12.9a –6.1 –6.2
Receiving red blood cell transfusion (%) –45.6a –21.7a –23.9a
Mechanical ventilation instituted (%) +0.8 +14.6a +15.0c
Pulmonary artery catheter use (%) +3.4 +10.6e +13.9b
A negative or positive value indicates how the control group therapy compares with the treatment group. a P < 0.001, b P = 0.01, c P = 0.02, 
d P = 0.03, e P = 0.04. EGDT, early goal-directed therapy.
Table 4
Outcome measures: percentage change or improvement,
baseline to 72 hours
Outcome measure Control Treatment P value
ScvO2* 32.7 44.9 0.001
Lactate* 43.5 61.0 0.02
Base deficit* 42.7 77.5 0.001
pH* 5.4 12.3 0.001
APACHE II* 24.5 40.2 0.002
Mortality in hospital 46.5 30.5 0.009
Mortality at 28 days 49.2 33.3 0.01
Mortality at 60 days 56.9 44.3 0.03
Length of hospital stay† – 20.7 0.04
APACHE II, Acute Physiology and Chronic Health Evaluation; ScvO2,
central venous oxygen saturation. * Baseline to 72 hours. † Surviving to
hospital discharge.S7
it is possible to identify patients with profound global myocar-
dial dysfunction who are hence at risk of impaired perfusion.
These patients, almost 15% of those in the EGDT group,
received dobutamine during the first 6 hours because
myocardial suppression was diagnosed. Once myocardial
dysfunction is corrected (and compliance improved), these
patients become more suitable for volume loading, so this
group received almost 3.5 liters more fluids in the first
6 hours than the control patients. Therefore, although vaso-
pressor use was similar in the first 6 hours, patients in the
EGDT group were more aggressively weaned off these
agents during this period, resulting in fewer patients in this
group entering the ICU on vasopressors than in the control
group. The lack of aggressive volume loading in the control
group led to greater use of vasopressors in patients over the
subsequent 72 hours. In spite of more volume loading, the
EGDT group received less mechanical ventilation over the
subsequent 72 hours than in the standard treatment group.
Why was cardiovascular collapse a significant cause of
death in the control group?
Cryptic shock (shock with normal vital signs) is a frequent
occurrence in early severe sepsis and septic shock. Despite
resuscitation to the goals for mean arterial blood pressure
and CVP, almost 40% of control patients continued to exhibit
global tissue hypoxia (decreased ScvO2 and increased
lactate levels); in these patients, there was a twofold increase
in hemodynamic deterioration, requiring more mechanical
ventilation, pulmonary artery catheterization, and vasopressor
use in the subsequent 72 hours.
How do severe sepsis and septic shock differ
hemodynamically in the early stages compared with that
classically described in the ICU?
Patients presenting with early sepsis and septic shock are
characterized by hypovolemia (low CVP), normal to increased
blood pressures, and decreased cardiac output (decreased
central venous oxygen saturation and low cardiac index). This
is in contrast to ICU patients who are euvolemic, have high
ScvO2, and have elevated cardiac indices [29].
What are the most important ways in which EGDT can
improve outcomes?
The key factors are early detection of high-risk patients in
cryptic shock, early reversal of hemodynamic perturbations
and global tissue hypoxia, prevention of acute cardiovascular
collapse, and the possibility of preventing the inflammatory
aspects of global tissue hypoxia that accompany the inflam-
mation or infection.
Recommendations of the panel
Severe sepsis and septic shock patients should receive
early aggressive therapy to restore and maintain oxygen
availability to the cells. There should also be generous use
of fluids and inotropic agents titrated by appropriate hemo-
dynamic monitoring.
Drotrecogin alfa (activated)
Background
A large number of observational studies have shown that
patients with sepsis have severe depletion of protein C
[30,31]. A number of studies have also shown the associa-
tion of protein C depletion with high mortality in sepsis
[32–34]. Furthermore, baboon studies have demonstrated
that treatment with activated protein C prevents death from
live Escherichia coli infusions [35,36].
Activated protein C exerts a number of actions. Anticoagulant
action includes the inactivation of coagulation factors Va and
VIIIa, and the inhibition of the formation of thrombin. Profibrino-
lytic action allows the activity of tissue plasminogen activator
(endogenous tissue plasminogen activator), by inactivating
plasminogen activator inhibitor 1 and thrombin activatable fib-
rinolysis inhibitor. Finally, anti-inflammatory action reduces IL-6
(in vivo) and proinflammatory cytokines (in vitro).
The specific mechanisms by which drotrecogin alfa (acti-
vated) exerts its effect on survival in patients with severe
sepsis are not completely understood.
The efficacy of drotrecogin alfa (activated) (recombinant
human activated protein C) in reducing mortality in patients
with severe sepsis was investigated in a large multicenter,
blinded, placebo-controlled, randomized, phase III clinical
trial, the Protein C Worldwide Evaluation in Severe Sepsis
(PROWESS) trial [14]. All patients in the PROWESS trial
received standard supportive care in addition to either
drotrecogin alfa (activated) or placebo.
Protocol
For a summary of the protocol used in the PROWESS study,
see Appendix 3.
Key data
The overall mortality in patients treated with drotrecogin alfa
(activated) was 24.7% compared with 30.8% in patients
receiving placebo, an absolute risk reduction of 6.1%
(P = 0.006) (see Fig. 4). The absolute risk reduction in
patients with high risk of death defined by an APACHE II
score ≥25 was 12.8% (P < 0.001). The absolute risk reduc-
tion in patients with high risk of death defined by multiple
organ failure was 7.4% (P = 0.006).
No substantial differences in drotrecogin alfa (activated)
treatment effects were observed in subgroups defined by
gender, ethnic origin, or infectious agent.
Implications and further questions
Can drotrecogin alfa (activated) be used in patients on
dialysis for pre-existing renal failure, a category that was
specifically excluded in the PROWESS trial?
No pharmacokinetic data were available on drotrecogin alfa
(activated) in patients on chronic dialysis when the
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PROWESS trial began, so such patients were excluded from
the trial. Subsequent research has shown that the pharmaco-
kinetics of drotrecogin alfa (activated) are not substantially
changed in patients on chronic dialysis.
How relevant is the 48-hour maximum treatment window to
clinical practice?
The design of the PROWESS trial allowed a maximum of
48 hours between the onset of first organ dysfunction and
the receipt of drotrecogin alfa (activated) (a 24-hour
window was allowed for receipt of the drug following the
first confirmation of first organ dysfunction, which in turn
had to have been present for no more than 24 hours). The
treatment effect of drotrecogin alfa (activated) was consis-
tent across all time intervals from meeting the entry criteria
to the receipt of the study drug. Treatment with drotrecogin
alfa (activated) thus does not appear to be as time critical
as interventions such as tissue plasminogen activator in
stroke or myocardial infarction. Because most of the experi-
ence with drotrecogin alfa (activated) was based on organ
failure times less than 48 hours, treatment should not be
delayed when an appropriate candidate is identified. The
time window employed in the PROWESS trial should allow
a full history to be taken and other tests to be performed to
determine the bleeding risk.
Does the bleeding risk vary among patient subgroups?
As with all anticoagulants, drotrecogin alfa (activated) is
associated with a risk of severe bleeding. During the infusion
period in the PROWESS trial, the bleeding rates were 2.4%
in the drotrecogin alfa (activated) group versus 1.0% in the
placebo group (P = 0.024). The risk of bleeding was fairly
constant across most subgroups. However, severe thrombo-
cytopenia (<30,000/mm3) was commonly associated with
serious bleeding and intracerebral hemorrhage.
What criteria should be used to identify patients who may
benefit from drotrecogin alfa (activated)?
Patients at high risk of death in the PROWESS trial were
most likely to benefit from drotrecogin alfa (activated). In the
PROWESS trial, the APACHE II score was the most effective
predictor of risk of death and likelihood of benefit from
drotrecogin alfa (activated), particularly in those patients with
an APACHE II score ≥25.
In the PROWESS trial, the number of organ dysfunctions
was also an important indicator that supported an association
between likelihood of benefit from drotrecogin alfa (activated)
and risk of death. Two or more organ dysfunctions identify a
population that responds well to therapy, and is a practical
measurement.
If a patient has one organ dysfunction and looks likely to
develop a second, should we delay treatment with
drotrecogin alfa (activated)?
The panel believes that acute respiratory failure or hypoten-
sion unresponsive to fluid challenge should suggest the use
of drotrecogin alfa (activated). However, coagulopathy, a
platelet count <80,000/mm3, acidosis, or low urine output
alone should not suggest its use.
A very large international study of 11,500 patients will be
started in late 2002 to investigate the efficacy of drotrecogin
alfa (activated) in patients with a single organ failure and/or
APACHE scores <25.
Should we only prescribe drotrecogin alfa (activated) to
patients in the ICU or can it be given beforehand?
The decision on whether to administer the drug should
ultimately depend on whether the patient meets the selection
criteria. A patient presenting in the emergency room with
acute respiratory failure or acute cardiovascular decompen-
sation should receive appropriate treatment there.
The drawback to treatment in the emergency room is that
there may not be sufficient time in which to evaluate the
patient’s bleeding risks. Delaying treatment for a few hours
will enable more tests to be performed and a fuller history to
be taken, both of which will provide a better indication of
whether drotrecogin alfa (activated) is appropriate.
Do the treatment dose of drotrecogin alfa (activated) and the
duration of therapy remain the same under all
circumstances?
The dose is always the same (24 µg/kg/hour), regardless of
the type of organ failure or the degree of sepsis severity. In
addition, the 96-hour window of treatment is always the same
so that interruptions of treatment are made up at the end to
maintain a total of 96 hours of treatment.
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Figure 4
Twenty-eight-day survival in patients treated with drotrecogin alfa
(activated) or placebo: all-cause mortality.
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Do patients require any laboratory testing before they
receive drotrecogin alfa (activated)?
No laboratory testing was carried out in the PROWESS
trial, and subgroup analysis identified no biochemical
marker that conclusively indicates treatment. For example,
treatment-associated reductions in mortality were observed
in patients with normal protein C levels and in those with
low protein C levels. Clinical criteria are recommended for
the initiation of therapy.
Can drotrecogin alfa (activated) be given to a patient with
severe sepsis who is on anticoagulants (e.g. warfarin) or
antiplatelet agents (e.g. aspirin or glycoprotein IIb/IIIa
inhibitors) for cardiac disease?
Aspirin (650 mg/day) was allowed in the PROWESS trial.
Patients on glycoprotein IIb/IIIa inhibitors were excluded
because no data were available regarding drug interactions
and pharmacokinetics. Use of these types of agents is likely
to increase the risk of bleeding with drotrecogin alfa (acti-
vated) therapy. The anticipated benefits must therefore be
weighed against the potential risks. In the PROWESS trial,
efforts were made to correct the international normalized ratio
towards normal if it was greater than 3 at any time during infu-
sion of drotrecogin alfa (activated).
Is it acceptable to treat concomitantly with steroids?
Approximately one-third of patients in the PROWESS trial
received steroids at the same time as drotrecogin alfa (acti-
vated). There was no interaction with steroid use, presumably
because the mechanism of action of steroids is so different
from that of activated protein C. Hence, steroids should be
used if they are needed, and if the patient qualifies for
drotrecogin alfa (activated) the two should be used together.
Recommendations of the panel
Drotrecogin alfa (activated) should be considered for use in
all adult patients with recent onset severe sepsis or septic
shock, and a high risk of death.
Moderate-dose corticosteroids
Background
The value of steroids in the treatment of patients with severe
sepsis and septic shock has been fiercely debated for some
time. Although a number of well-designed, randomized, con-
trolled trials failed to show any benefits of steroid therapy in
terms of improved survival in patients with severe sepsis
(reviewed in [37,38]), with mortality increased in many as a
result of an increased incidence of nosocomial infections,
these trials were primarily investigating the efficacy of short
courses of high-dose steroids. The question of whether lower
doses of steroids may provide benefit in these patients has
only recently been addressed.
There is a relatively strong rationale for considering the use of
steroids in patients with refractory septic shock. Relative
adrenal insufficiency is common in patients with refractory
septic shock (50–75% of patients) [39]. In addition to such
relative adrenal insufficiency and the blunted response to
corticotrophin, a large body of evidence indicates that sepsis
and refractory septic shock are characterized by peripheral
tissue resistance to corticosteroids [40,41]. In septic
patients, this can be evidenced in a variety of ways. First,
global cortisol binding, which carries cortisol from the adrenal
glands to the tissues, decreases in patients with severe
sepsis [42]. Second, the number and binding affinity of
glucocorticosteroid receptors may be reduced in patients
with sepsis and severe sepsis [43], leading to a decrease in
the conversion of cortisone to its active form, cortisol, particu-
larly by IL-2 levels in the tissues. Finally, data have been
published demonstrating that moderate doses of steroids
may restore cell sensitivity to vasopressors [44]. This may
reduce the intensity of the inflammatory response and
decrease organ dysfunction. Low-dose steroid treatment is
also well tolerated [40].
This body of evidence prompted the initiation of a phase III
randomized, controlled trial performed in 19 centers in France
with 300 patients [45]. The aim of the trial was to determine
whether moderate-dose corticosteroid therapy affected sur-
vival in patients with refractory septic shock and adrenal
insufficiency.
Protocol
All patients had to be treated with vasopressor agents and
mechanical ventilation. For a summary of the protocol used in
this study, see Appendix 4.
Key data
Patients were stratified according to their response to the
adrenocorticotrophic hormone (ACTH) test. Nonresponders
were defined by an increment in cortisol levels <9 µg/dl or
<250 nM/l after challenge with 250 µg cosyntropin. Of the 300
patients included, there were 229 nonresponders to the corti-
cotropin test (placebo, 115 patients; steroids, 114 patients). A
significant survival benefit was demonstrated among non-
responders receiving moderate-dose corticosteroids. There
were 73 deaths in the placebo group (63%) and 60 deaths in
the steroid group (53%) (hazard ratio, 0.67; 95% confidence
interval, 0.47–0.95; P = 0.023).
Implications and further questions
Should corticosteroid administration be guided by the
ACTH test?
No beneficial effects were observed in the subset of patients
who were classified as responders. Hence, in this paradigm,
the ACTH test serves as a useful prognostic measure. Since
a beneficial effect was observed in the total population,
however, the need for an ACTH test can be challenged and
further studies are required.
If an ACTH test is performed, corticosteroid administration
can be started before results are received.
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What is the optimal timing for this intervention?
Moderate-dose corticosteroids should be administered to
patients with established refractory septic shock.
What is the optimal dose for this intervention?
Hydrocortisone should be given daily at a dose of
200–300 mg. Fludrocortisone should be given daily at a dose
of 50 µg.
What is the optimal duration for this intervention?
Moderate doses of steroids should be given for 7 days.
Should hydrocortisone be given as a continuous infusion?
Hydrocortisone can be administered as serial boluses or as a
continuous infusion. It may be that rebound phenomena at
treatment discontinuation are more frequent when hydro-
cortisone is given as a continuous infusion. In addition, in the
phase III randomized trial, hydrocortisone was given as serial
boluses.
Should a mineralocorticoid be systematically added to
hydrocortisone?
The phase III randomized trial has shown that the combination
of hydrocortisone and fludrocortisone increased survival. In
addition, sepsis is more frequently associated with a
mineralocorticoid deficiency than a glucocorticoid deficiency.
Hence, fludrocortisone should be added to hydrocortisone.
Recommendations of the panel
Administration of moderate-dose corticosteroids should be
considered in cases of refractory septic shock, particularly in
those with relative adrenal insufficiency. It is recommended that
an ACTH test be carried out before starting the intervention.
Tight control of blood sugar
Background
Hyperglycemia, caused by insulin resistance in the liver and
muscle, is a common finding in ICU patients. It can be con-
sidered an adaptive response, providing glucose for the
brain, red cells, and wound healing, and is generally only
treated when blood glucose increases to >215 mg/dl
(>12 mmol/l).
Previous studies have shown that high levels of insulin-like
growth factor binding protein 1 (a very good marker of lack of
hepatic insulin effect) predict mortality [46,47]. Patients with
high insulin-like growth factor binding protein 1 also tend to
have the lowest insulin levels, indicating that beta cell func-
tion is impaired and, therefore, not enough insulin is being
produced. These results indicate that hyperglycemia may not
always be adaptive and that it should be treated to avoid the
onset of specific complications.
Nevertheless, conventional wisdom in the ICU has been that
hyperglycemia is beneficial and that hypoglycemia should be
avoided.
The hypothesis that hyperglycemia (>110 mg/dl, >6.1 mmol/l)
predisposes to specific ICU complications, prolonged inten-
sive care dependency and death was tested in a prospective,
randomized, controlled trial [48].
Protocol
For a summary of the protocol used in this study, see
Appendix 5.
Key data
Thirty-five of the 765 patients (4.6%) in the intensive insulin
group died in the ICU, compared with 63 patients (8.0%) in
the conventional therapy group. For further mortality data on
both the length of hospital stay and the cause of death, see
Tables 5 and 6. For morbidity data, see Figure 5.
Implications
Tight control of blood sugar, as outlined in Appendix 5,
requires a strict protocol for insulin administration and
repeated determination of blood sugar.
Further questions
Since the study was mainly in surgical patients, would this
intervention be suitable for medical patients in the ICU?
This is yet to be proven, and is the subject of an ongoing
study. Because medical patients tend to stay in the ICU
longer than surgical patients, the results from this study indi-
cate that this intervention would be even more favorable to
medical ICU patients. However, one needs to be careful with
application of the algorithm in certain disease states, espe-
cially severe hepatic dysfunction and renal failure.
Does the glucose intake only include intravenous glucose?
No, all carbohydrates are included. See Appendix 5 for guide-
lines on feeding.
Why was this level of blood glucose chosen?
The level was chosen because it is in the physiologic range
for healthy people.
Is it insulin that is important or simply better control of blood
sugar?
As well as its effect on glycemia, insulin has been shown to
inhibit TNF-α and macrophage inhibitory factor (when infused
concomitantly with glucose). This has led to some doubts as
to whether the effect in this study was due to normalization of
blood glucose levels. However, multivariate analysis of all the
risk factors for mortality, including severity of illness on admis-
sion, indicated that blood glucose determines the outcome;
there was a 75% increase in risk of death per 50 mg/dl
increase in blood glucose.
Would glucose control with another drug have the same effect?
It is not yet possible to determine this. Although it was blood
glucose levels that were measured, the effects of insulin may
in fact be on free fatty acids, as they change in parallel with
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blood glucose. One of the key mechanisms may be preven-
tion of hypertriglyceridemia and high concentrations of free
fatty acids.
Recommendations of the panel
It is strongly advisable to tightly control blood sugar close to
physiologic levels, especially in surgical patients. Implemen-
tation of this recommendation requires a well-defined ICU
protocol.
Optimal outcomes through appropriate
patient identification and appropriate timing
of therapy
The interventions discussed in the present article have been
applied in different patient populations and at different times
in the course of the disease (see Table 7).
It is essential for physicians to understand that these thera-
pies are not mutually exclusive. Optimal patient management
may require a combination of approaches: mechanical ventila-
tion to preserve lung function, hemodynamic support to main-
tain adequate ScvO2, intensive insulin therapy to normalize
blood sugar, steroids to provide adequate immunosuppres-
sion, and drotrecogin alfa (activated) to prevent the systemic
coagulopathy characteristic of severe sepsis and, hence, to
preserve organ function. A sound understanding of the indi-
cations and contraindications of these interventions will guide
appropriate intervention.
Similarly, the timing of therapy needs to be closely monitored.
Education in the signs and symptoms of sepsis and severe
sepsis should prompt early initiation of therapy. Many of the
interventions discussed in this article were tested at specific
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Table 5
Mortality results [46]
Insulin treatment (%)
Mortality Conventional (n = 783) Intensive (n = 765) P value
Intensive care unit deaths (n = 1548) 8.0 4.6 0.005*
5-Day mortality rate 1.8 1.7 0.9
Long-stayers (n = 451) 20.2 10.6 0.005
In-hospital deaths (n = 1548) 10.9 7.2 0.01
Long-stayers (n = 451) 26.3 16.8 0.01
*After correction for multiple interim analyses, adjusted P = 0.036.
Table 6
Mortality: total number of patients from various causes of death [46]
Insulin treatment
Cause of death Conventional (n = 783) Intensive (n = 765) P value
Total number 0.02
Acute cardiovascular collapse 7 10
Severe brain damage 5 3
Multiple organ failure, no sepsis focus 18 14
Multiple organ failure, with sepsis focus 33 8
Figure 5
Most important effects on morbidity [46]. CVVH, continuous
venovenous hemofiltration; ICU, intensive care unit; NNT, number
needed to treat; RRR, relative risk reduction.
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points in the evolution of sepsis, yet in clinical practice their
use may be required at a different stage of disease. For
example, a large trial of drotrecogin alfa (activated) will deter-
mine the efficacy of the drug in patients with a single organ
failure or APACHE II score <25.
How can use of these new interventions be
encouraged among the general ICU
community?
Despite the wealth of data to support the approaches dis-
cussed, it is clear that uptake of these interventions into clini-
cal practice has been slow. Although there may be practical
reasons for this, it would appear in many cases to involve
either unfamiliarity with the data or a reluctance, or at least
inertia, to change established practices (witness the neces-
sity of proving that hypoglycemia is beneficial in ICU patients
despite no good evidence to the contrary).
The ICU has changed in the past 30 years; there are more
tools to use and more interventions to implement. Despite
application of new methods, however, outcomes have
changed very little and certainly not in proportion to the
changes that were expected based on the results from clini-
cal trials. Efficient integration of new interventions into the
wider ICU population is clearly essential.
The panel believes that optimal use of existing therapies and
the integration of proven new therapies will reduce mortality
rates. Further positive results from new trials with improved
trial designs should encourage intensivists to incorporate
new interventions into their practice.
Protocols
Protocols are essential to ensure efficient integration of new
therapies and to improve outcomes on the wards. Morris pre-
dicted in a recent paper that an increase in compliance with
evidence-based recommendations through the use of proto-
cols would decrease error and would enhance patient safety
[49]. However, a complete treatment protocol is only effective
when each ward (inside and outside of the ICU) has the
trained staff to implement it, and when a skilled intensive care
physician is available to lead the team. Training and education
of staff is essential.
Education
An initiative discussed recently (March 2002) in Brussels at a
roundtable conference sponsored by the European Society
of Intensive Care Medicine and the Society of Critical Care
Medicine was to expand the scope of ICU care to the pre-
ICU setting, and even up to 1 year post-ICU, so as to develop
a better understanding of the issues surrounding ICU care. A
commonly used term is that there are ‘doctors without
borders’. Similarly, there should be ICU physicians without
borders. There is a belief among many physicians that a
patient only becomes an ICU patient on arrival at the unit, yet
there are many critically ill patients in non-ICU settings.
Disease definitions need to be broadened to such an extent
that they are no longer by location.
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Table 7
Summary of the five interventions and recommendations of the panel on clinical application of each
Intervention Patient population studied Timing of intervention Recommendations of the panel
Low tidal volume ALI/ARDS patients fulfilling blood  Evidence of ALI/ARDS. Earlier  Tidal volume should be limited to 
gas criteria and with bilateral infiltrates application warranted in patients with  ~6 ml/kg in patients with 
sepsis likely to develop ALI/ARDS ALI/ARDS requiring mechanical 
ventilation
Early goal-directed  Emergency room patients with two out  Pre entry into the ICU Severe sepsis and septic shock 
therapy of the four SIRS criteria and systolic  patients should receive early 
blood pressure ≤ 90 mmHg or  aggressive hemodynamic therapy, 
lactate ≥ 4 mmol/l and fluids and inotropic agents 
where indicated
Drotrecogin alfa  Severe sepsis patients as defined by  Within 48 hours of diagnosis of the  Patients with severe sepsis and 
(activated) three or more SIRS criteria plus at least  most recent organ dysfunction high risk of death (e.g. APACHE II 
one acute organ dysfunction score ≥ 25, or two or more organ 
dysfunctions)
Moderate-dose  Refractory septic shock As soon as refractory septic shock  Administer to refractory septic 
corticosteroids develops shock patients, particularly those 
with relative adrenal insufficiency, 
after an ACTH test has been 
carried out
Tight control of  Mostly surgery patients with SIRS  ICU admission Tightly control blood sugar close 
blood sugar or sepsis to physiologic levels
ACTH, adrenocorticotrophic hormone; ALI, acute lung injury; APACHE II, Acute Physiology and Chronic Health Evaluation II; ARDS, acute
respiratory distress syndrome; ICU, intensive care unit; SIRS, systemic inflammatory response syndrome.S13
Conclusion
All five of the interventions discussed in this article have gen-
erated convincing evidence for their use, and they hold out
hope for reducing mortality in patients with sepsis, severe
sepsis and septic shock. Yet, despite compelling data, the
application of these interventions has yet to become routine
practice in most ICUs.
It is our hope that this article will enable physicians to under-
stand how best to apply these therapies in clinical practice; from
appropriate patient selection and timing of therapy, to combin-
ing different approaches for optimal patient management.
A willingness to embrace new interventions, coupled with the
development and implementation of rigorous protocols to
ensure appropriate use, will improve outcomes and lead to a
substantial reduction in mortality in these patients.
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Appendix 1: low tidal volume
Patient selection
Inclusion criteria
• Partial pressure of arterial oxygen/FiO2 ≤300 mmHg.
• Bilateral infiltrates consistent with pulmonary edema on
frontal chest radiograph.
• No clinical evidence of left atrial hypertension, pulmonary
artery wedge pressure ≤18 mmHg if measured.
• Positive pressure ventilation via endotracheal tube.
Appendix 1 Table 1
National Institutes of Health Acute Respiratory Distress Syndrome Network lower tidal volume ventilation for acute lung
injury/acute respiratory distress syndrome protocol summary
Variable Protocol
Ventilator mode Volume assist control
Tidal volume ≤ 6 ml/kg predicted body weight (subsequent adjustments were made to maintain plateau pressure 
≤ 30 cmH2O)
Plateau pressure ≤ 30 cmH2O
Ventilation set rate/pH goal 6–35 breaths/min, adjusted to achieve arterial pH 7.3–7.45 if possible
Inspiratory flow, I:E Adjust flow to achieve I:E of 1:1–1:3
Oxygenation goal PaO2 of 55 ≤ 80 mmHg, or SpO2 of 88% ≤ 95%
FiO2/PEEP (mmHg) combinations 0.3/5, 0.4/5, 0.4/8, 0.5/8, 0.5/10, 0.6/10, 0.7/10, 0.7/12, 0.7/14, 0.8/14, 0.9/14, 0.9/16, 0.9/18, 1.0/18, 
1.0/22, 1.0/24
Weaning Attempts to wean by pressure support required when FiO2/PEEP ≤ 0.40/8
FiO2, fraction of inspired oxygen; I:E, inspiration:expiration; PaO2, partial pressure of arterial oxygen; PEEP, positive end-expiratory pressure; SpO2,
oxygen saturation via pulse oximetry.S15
Exclusion criteria
• 36 hours had elapsed since they met the first three inclu-
sion criteria.
• Younger than 18 years old.
• Participated in other trials within 30 days before the first
three criteria were met.
• Pregnant.
• Increased intracranial pressure.
• Neuromuscular disease that could impair spontaneous
breathing.
• Sickle cell disease.
• Severe chronic respiratory disease.
• Weighed more than 1 kg per centimeter of height.
• Burns over more than 30% of their body surface area.
• Other conditions with an estimated 6-month mortality rate
greater than 50%.
• Undergone bone marrow or lung transplantation.
• Chronic liver disease (as defined by Child–Pugh class C).
• Attending physician refused or was unwilling to agree to
the use of full life support.
Appendix 2: early goal-directed
therapy
Patient selection
Inclusion criteria
• Fulfillment of at least two out of the four systemic inflam-
matory response syndrome criteria and systolic blood
pressure  ≤90 mmHg after a 20–30 ml/kg volume chal-
lenge over 30 min, or
• Fulfillment of at least two of the four systemic inflamma-
tory response syndrome criteria and lactate ≥4 mmol/l.
Exclusion criteria
• Younger than 18 years old.
• Pregnant.
• Presence of an acute cerebral vascular event.
• Acute coronary syndrome.
• Acute pulmonary edema.
• Status asthmaticus.
• Cardiac dysrhythmias.
• Contraindication to central venous catheterization.
• Active gastrointestinal hemorrhage.
• Seizure.
• Drug overdose.
• Burn injury.
• Trauma.
• Requirement for immediate surgery.
• Uncured cancer (during chemotherapy).
• Immunosuppression (due to organ transplantation or
systemic disease).
• Do-not-resuscitate status.
• Advanced directives restricting implementation of the
protocol.
Protocol
When the CVP, MAP and ScvO2 are optimized to the levels
presented in Appendix 2 Table 1, if ScvO2 <70%, then
administer 2.5 µg/kg/min dobutamine. Increase the dose by
2.5 µg/kg/min every 30 min until ScvO2 ≥70% or the dose of
dobutamine has reached 20 µg/kg/min.
Decrease the dobutamine dose if MAP <65 mmHg or if heart
rate >110 beats/min. Decrease the oxygen consumption in
patients in whom hemodynamic optimization could not be
achieved using mechanical ventilation and sedatives.
Appendix 3: drotrecogin alfa
(activated)
Inclusion criteria
Infection criteria
Patients must have a known infection or a suspected infec-
tion, as evidenced by one or more of the following:
• White cells in a normally sterile body fluid.
• Perforated viscus.
• Radiographic evidence of pneumonia in association with
the production of purulent sputum.
• A syndrome associated with a high risk of infection (e.g.
ascending cholangitis).
Modified systemic inflammatory response syndrome
criteria
Patients should meet at least three of the following four
criteria:
• A core temperature ≥38°C (100.4°F) or ≤36°C (96.8°F).
• A heart rate ≥90 beats/min, except in patients with a
medical condition known to increase the heart rate or
those receiving treatment that would prevent tachycardia.
Available online http://ccforum.com/content/6/S3/S1
Appendix 2 Table 1
Optimized levels for central venous pressure, mean arterial pressure, and central venous oxygen saturation (ScvO2)
Variable Protocol
Central venous pressure 8–12 mmHg (achieved by giving a 500 ml bolus of crystalloid every 30 min)
Mean arterial pressure ≥ 65 ≤ 90 mmHg (if < 65 mmHg, give vasopressors; if > 90 mmHg, give vasodilators)
ScvO2 If < 70%, transfuse with red cells to reach an hematocrit of ≥ 30%S16
• A respiratory rate ≥20 breaths/min or a partial pressure of
arterial carbon dioxide ≤32 mmHg, or the use of mechani-
cal ventilation for an acute respiratory process.
• A white cell count ≥12,000/mm3 or ≤4000/mm3, or a dif-
ferential count showing >10% immature neutrophils.
Criteria for dysfunctional organs or systems
Patients should meet at least one of the following five criteria:
• Cardiovascular system dysfunction: arterial systolic blood
pressure  ≤90 mmHg or MAP ≤70 mmHg for at least
1 hour despite adequate fluid resuscitation, adequate
intravascular volume status or the use of vasopressors in
an attempt to maintain a systolic blood pressure
≥90 mmHg or a MAP ≥70 mmHg.
• Kidney dysfunction: urine output <0.5 ml/kg per hour for
1 hour, despite adequate fluid resuscitation.
• Respiratory system dysfunction: ratio of partial pressure
of arterial oxygen to FiO2 ≤250 in the presence of other
dysfunctional organs or systems, or ratio ≤200 if the lung
was the only dysfunctional organ.
• Hematologic dysfunction: platelet count <80,000/mm3 or to
have decreased by 50% in the 3 days preceding enrollment.
• Unexplained metabolic acidosis: pH ≤7.30 or base deficit
≥5.0 mmol/l in association with a plasma lactate level
>1.5 times the upper limit of the normal value for the
reporting laboratory.
Exclusion criteria
• Pregnancy or breastfeeding.
• Aged younger than 18 years or weight >135 kg.
• Platelet count <30,000/mm3.
• Conditions that increase the risk of bleeding:
• surgery requiring general or spinal anesthesia within
12 hours before the infusion, the potential need for
such surgery during the infusion, or evidence of active
bleeding postoperatively;
• a history of severe head trauma requiring hospitaliza-
tion, intracranial surgery, or stroke within 3 months
before the study, or any history of intracerebral arteri-
ovenous malformation, cerebral aneurysm, or mass
lesions of the central nervous system;
• a history of congenital bleeding diatheses; gastro-
intestinal bleeding within 6 weeks before the study
unless corrective surgery had been performed; or
• trauma considered to increase the risk of bleeding.
• A known hypercoagualable condition including:
• resistance to activated protein C;
• hereditary deficiency of protein C, protein S, or
antithrombin III;
• presence of anticardiolipin antibody, antiphospholipid
antibody, lupus anticoagulant, or homocysteinemia; or
• recently documented (within 3 months) or highly sus-
pected deep-vein thrombosis or pulmonary embolism.
• Patient’s family or physician, or both, not in favor of
aggressive treatment of the patient, or the presence of an
advanced directive to withhold life-sustaining treatment.
• Patient not expected to survive 28 days because of an
uncorrectable medical condition, such as poorly con-
trolled neoplasm or other end-stage disease.
• Moribund state in which death is perceived to be imminent.
• Human immunodeficiency virus infection in association
with a last known CD4 cell count ≤50/mm3.
• History of bone marrow, lung, liver, pancreas, or small-
bowel transplantation.
• Chronic renal failure requiring hemodialysis or peritoneal
dialysis (acute renal failure was not an exclusion criterion).
• Known or suspected portosystemic hypertension, chronic
jaundice, cirrhosis, or chronic ascites.
• Acute pancreatitis with no established source of infection.
• Participation in an investigational study within 30 days
before treatment.
• Use of any of the following medications or treatment regi-
mens:
• unfractionated heparin to treat an active thrombotic
event within 8 hours before the infusion (prophylactic
treatment with a dose of unfractionated heparin of up
to 15,000 U/day was permitted);
• low molecular weight heparin at a higher dose than
recommended for prophylactic use (as specified in the
package insert) within 12 hours before the infusion;
• warfarin (if used within 7 days before study entry and if
the prothrombin time exceeded the upper limit of the
normal range for the institution);
• acetylsalicylic acid at a dose of more than 650 mg/day
within 3 days before the study;
• thrombolytic therapy within 3 days before the study
(thrombolytic agents permitted for the treatment of
thromboses within a catheter);
• glycoprotein IIb/IIIa antagonists within 7 days before
study entry;
• antithrombin III at a dose of more than 10,000 U within
12 hours before the study;
• protein C within 24 hours before the study.
Dosage
Drotrecogin alfa (activated) should be given at a dose of
24 µg/kg/hour for 96 hours.
Infusion should be interrupted 1 hour prior to any percuta-
neous procedure or major surgery, and should be resumed 
1 and 12 hours later, respectively, in the absence of bleeding
complications.
Appendix 4: moderate-dose
corticosteroids
Patient selection
Inclusion criteria
• Aged 18 years or older.
• Documented site(s) of infection.
• Temperature >38.3°C or <35.6°C.
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• Heart rate >90 beats/min.
• Systolic blood pressure <90 mmHg (fluids and
>5µg/kg/min dopamine).
• Mechanical ventilation.
• Partial pressure of arterial oxygen/FiO2 <280, urine
output <0.5 ml/kg/hour or lactate >2 mmol/l.
• ACTH test.
Exclusion criteria
• Pregnancy
• AMI, pulmonary embolism
• Corticotherapy.
• Contraindication to steroids.
Protocol
There was an 8-hour time window from shock onset to check
for eligibility and to perform a short ACTH test (blood
samples before and 30 and 60 min after a 250 µg intra-
venous bolus of tetracosactrin). Patients were then randomly
assigned to receive 50 mg hydrocortisone as an intravenous
bolus every 6 hours and one 50 µg tablet of fludrocortisone
through a nasogastric tube once a day, or their respective
placebos. Treatments were given for 7 days, and patients
were followed up for 1 year.
Appendix 5: tight control of
blood sugar
Patient selection
The study included all mechanically ventilated patients enter-
ing the ICU: predominantly surgical patients, with some neu-
rological patients (the ICU in which the trial took place also
sees such patients). Medical ICU patients (e.g. those with
chronic obstructive pulmonary disease or oncologic or hema-
tological disorders) were not included as they are not treated
in the unit where the study was conducted. However, septic
patients that were initially surgical but then came back from
the ward with sepsis were included.
Only those patients who were moribund or had do-not-
resuscitate status at ICU admission were excluded from the trial.
Protocol
Intensive insulin treatment
If blood glucose ≥110 mg/dl (≥6.1 mmol/l), infuse with insulin
to maintain normoglycemia (80–110 mg/dl, 4.4–6.1 mmol/l).
Do not exceed 50 IU/hour.
Insulin adjustments
Adjust insulin dose based on measurements of whole-blood
glucose in undiluted arterial blood, performed at 1–4 hour
intervals, based on the following algorithm: adjust the dose in
proportion to the observed change in blood glucose level (if
blood glucose decreases by 50% then the insulin dose
should be decreased by 50% and checked within the next
hour). Appendix 5 Table 1 provides information on the appro-
priate action depending on the blood glucose level. The
numerical instructions provided in Appendix 5 Table 1 are a
guide; insulin dosage should always be done with common
sense, proportionate to the previous changes in blood
glucose observed upon previous changes in dosage.
Available online http://ccforum.com/content/6/S3/S1
Appendix 5 Table 1
Appropriate action depending on blood glucose level
Test Blood glucose result (mg/dl) Action
A: Measure blood glucose on entry to ICU >220 Start insulin at a dose of 2–4 IU/h. Continue as per test B
220–110 Start insulin at a dose of 1–2 IU/h.  Continue as per test B
<110 Do not start insulin but continue blood glucose monitoring 
every 4 h.  Continue as per test A
B: Measure glucose every 1–2 h until in normal range >140 Increase insulin dose by 1–2 IU/h 
110–140 Increase insulin dose by 0.5–1 IU/h
Approaching normal range Adjust insulin dose by 0.1–0.5 IU/h.  Continue as per test C
C: Measure glucose every 4 h Approaching normal range Adjust insulin dose by 0.1–0.5 IU/h
Normal Leave insulin dose unchanged
Falling steeply Reduce insulin dose by half and check every 1–2 h
60–80  Reduce insulin dose and check blood glucose within 1 h
40–60  Stop insulin infusion, assure adequate baseline glucose 
intake and check blood glucose within 1 h
<40 Stop insulin infusion, assure adequate baseline glucose 
intake, administer glucose per 10 g IV boluses and check 
blood glucose within 1 hS18
Glucose consumption
On admission, patients should receive continuous intra-
venous glucose (200–300 g over 24 hours). After 24 hours,
total parenteral, combined parenteral and enteral, or total
enteral feeding should be instituted: 20–30 nonprotein
kcal/kg/day with a balanced composition (0.13–0.26 g nitro-
gen/kg/day and 20–40% nonprotein calories in the form of
lipids). Total enteral feeding should be attempted as early as
possible.
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